Mitochondria regulate the balance between lipid metabolism and storage in the skeletal muscle. Altered lipid transport, metabolism and storage influence the bioenergetics, redox status and insulin signalling, contributing to cardiac and neurological diseases. Lipid storage disorders (LSDs) are neurological disorders which entail intramuscular lipid accumulation and impaired mitochondrial bioenergetics in the skeletal muscle causing progressive myopathy with muscle weakness. However, the mitochondrial changes including molecular events associated with impaired lipid storage have not been completely understood in the human skeletal muscle. We carried out morphological and biochemical analysis of mitochondrial function in muscle biopsies of human subjects with LSDs (n = 7), compared to controls (n = 10). Routine histology, enzyme histochemistry and ultrastructural analysis indicated altered muscle cell morphology and mitochondrial structure. Protein profiling of the muscle mitochondria from LSD samples (n = 5) (vs. control, n = 5) by high-throughput mass spectrometric analysis revealed that impaired metabolic processes could contribute to mitochondrial dysfunction and ensuing myopathy in LSDs. We propose that impaired fatty acid and respiratory metabolism along with increased membrane permeability, elevated lipolysis and altered cristae entail mitochondrial dysfunction in LSDs. Some of these mechanisms were unique to LSD apart from others that were common to dystrophic and inflammatory muscle pathologies. Many differentially regulated mitochondrial proteins in LSD are linked with other human diseases, indicating that mitochondrial protection via targeted drugs could be a treatment modality in LSD and related metabolic diseases.
Primary mitochondrial diseases manifest as neurological disorders such as mitochondrial myopathies and are caused due to mutations in mitochondrial proteins, predominantly the respiratory complexes (DiMauro et al. 2013) . These alter protein activity and bioenergetics, leading to muscle wasting, weakness, cramps, etc. (Wang et al. 2010; Milone and Wong 2013) . On the contrary, non-mitochondrial muscle pathologies such as muscular dystrophies and inflammatory myopathies also display mitochondrial dysfunction owing to upstream events and non-genetic mechanisms (Niyazov et al. 2016) . Altered sarcolemma (Ramadasan-Nair et al. 2014) , loss of structural proteins (as in dysferlinopathy), inflammation (as in polymyositis), or intracellular morphological changes [as in distal myopathy with rimmed vacuoles (DMRV)] could alter mitochondrial function and proteome (Sunitha et al. 2016) . Similarly, lipid dynamics are linked to mitochondrial function, both regulating each other.
Mitochondria modulate the balance between lipid metabolism and storage in the skeletal muscle. b-oxidation of fatty acids (FAs) is linked to ATP production, mitochondrial respiration (Eaton 2002 ) and redox balance (Tocchetti et al. 2012) . Muscle mitochondria regulate the transport and b-oxidation flux of long-chain FAs (Eaton 2002; Lopaschuk et al. 2010) . Any alteration in lipid transport and metabolism (Fisher-Wellman and Neufer 2012; Muoio and Neufer 2012) contributes to cardiac and neurological disease (Lopaschuk et al. 2010) .
On the other hand, long-chain free FAs act as uncouplers and inhibitors of oxidative phosphorylation, alter the mitochondrial membrane potential (wm) and proton motive force (Scorrano et al. 2001; Bernardi et al. 2002; Penzo et al. 2002; Loskovich et al. 2005 ) thereby affecting the mitochondrial energetics, redox and signalling functions (Schonfeld and Wojtczak 2008) . Long-chain acyl-CoAs inhibit adenine nucleotide translocator (Ciapaite et al. 2005 (Ciapaite et al. , 2006 Klingenberg 2008) , which could alter the ATP content and wm, reduce the coenzyme Q content and increase oxidative stress (Ciapaite et al. 2006) . Precursors and metabolites of b-oxidation can promote mitochondrial uncoupling and oxidative stress (Coen and Goodpaster 2012; Cortassa et al. 2014) .
Lipid storage (LS) is another regulatory link between lipid metabolism and mitochondria. Cells protect themselves from lipotoxicity Penzo et al. 2002; Aon et al. 2014) partly by sequestering them as triacylglycerol within lipid droplets (LDs) (Greenberg et al. 2011; Walther and Farese 2012) . LDs are physically associated and metabolically regulated by mitochondria and directly interact with respiratory complexes (Walther and Farese 2009; Wang et al. 2010; Barbosa and Siniossoglou 2017) . Altered LS causes lipotoxicity and insulin resistance, as a result of mitochondrial damage (Muoio and Neufer 2012) .
Lipid storage disorders (LSDs) are inherited neurometabolic disorders which cause weakness, intramuscular lipid accumulation, impaired energy production (primary carnitine deficiency, neutral lipid storage myopathy and multiple acyl-CoA dehydrogenase deficiency) and episodic rhabdomyolysis triggered by fasting, infection or exercise (deficiency of carnitine palmitoyltransferase, very-long-chain acyl-CoA dehydrogenase, trifunctional protein, etc.) (SainiChohan et al. 2012) . Other inherited LSDs and FA oxidation disorders result in cardiac myopathy (Saini-Chohan et al. 2012) . Neutral LSD is associated with muscle weakness and cardiomyopathy (Reilich et al. 2011) .
We hypothesized that the influence of lipids on muscle mitochondrial function could be potentially addressed by studying LSDs. While LSDs are characterized in terms of disease, metabolic changes, genetics and diet, studies on the influence of lipid excess on mitochondrial function in the human muscle are non-existent. To address this, we carried out a thorough morphological and biochemical analysis of mitochondrial function in muscle biopsies of patients diagnosed morphologically/biochemically as LSDs.
Materials and methods

Materials
All chemicals and solvents were of analytical grade. Bulk chemicals and solvents were obtained from Sisco Research Laboratories (Mumbai, Maharashtra, India) and Merck (Whitehouse Station, NJ, USA). Fine chemicals, Nagarse and consumables for enzyme histochemistry were procured from Sigma-Aldrich (St. Louis, MO, USA). Consumables for routine histology were procured from BDH chemicals (Dawsonville, GA, USA). Antibodies against dystrophin [dys1 (RRID:AB_442080), dys2 (RRID:AB_442081) and dys3 (RRID:AB_442082)], sarcoglycans [a (RRID:AB_442041), b (RRID:AB_564136), c (RRID:AB_442096) and d (RRID: AB_442079)] and merosin (RRID:AB_442108) were procured from Novocastra Laboratories Limited (Newcastle Upon Tyne, UK). Chemicals for electron microscopy were procured from TAAB laboratories and equipment Ltd (Aldermaston, Berkshire, England). ATP:ADP quantitation kit was procured from Abcam (Cambridge, MA, USA). Proteomic grade trypsin was obtained from Promega (Madison, WI, USA). Tandem mass tag (TMT) isobaric labelling kit was obtained from Thermofisher Scientific (Waltham, MA, USA). Reagent kit to assay aspartate aminotransferase was obtained from Grenier Bio-One GMBH (Frickenhausen, Germany).
Study design
Muscle biopsies from confirmed cases of LSD (n = 7) and agematched healthy controls (n = 10) were utilized in this study. The cases were first characterized by clinical evaluation followed by confirmation of diagnosis by biochemical and histopathological analysis. Following morphological analysis and confirmation of LSD, muscle biopsies were subjected to estimation of ADP/ATP. Next, muscle mitochondria from LSD cases and controls were subjected to proteomic analysis [n = 5 samples (biological replicates) for LSD and n = 5 samples (biological replicates) as control], which included tryptic digestion, TMT labelling and mass spectrometric (MS) analysis (carried out in n = 2 technical replicates for each sample). The mitochondrial protein profile was compared across different samples to understand the molecular basis of mitochondria dysfunction in LSDs and later compared with other muscle pathologies. Results from the proteomics experiment were further confirmed by validation experiments (n = 3 experiments per group).
Human muscle biopsies
The study protocol was approved by the Institutional Ethics Committee (Approval reference number: NIMH/DO/ETHICS SUB-COMMITTEE/2014 Sl. No. 4). The study was not preregistered.
Patients with muscle diseases evaluated at the neuromuscular disorders clinic, NIMHANS, Bangalore, India, during 2012-2016 were selected following diagnostic procedures. The study included histopathologically confirmed cases of LSD (n = 7; male = 3, female = 4) in the age range 14-25 years and age-matched control (n = 10). Sample size calculation was not performed regarding the samples assessed in this study. All suspected LSD cases were subjected to blood-based tandem mass spectrometry for quantitative analysis of abnormal lipid metabolism as part of routine diagnostics, as described previously (Vengalil et al. 2017) .
The clinical details of all the patients were recorded. This included demographic details (age, gender, age at onset and presentation), family history, initial symptoms, easy fatigue, Myalgias, fever-induced worsening, Myoglobinuria, Dysphagia, neck drop, Creatine Kinase levels and assessment of muscle strength (both upper and lower limbs). After obtaining informed consent, biopsies were performed by a competent neurologist, under local anaesthesia. A moderately weak muscle (either from biceps or quadriceps) free from previous trauma was selected for uniformity and submitted for routine diagnosis to the Department of Neuropathology, NIMHANS, Bangalore, India. A fragment of the fresh biopsy was snap frozen in isopentane that was pre-cooled in liquid nitrogen and stored at À80°C (Sunitha et al. 2016 ) and used subsequently for biochemical and proteomics experiment. No randomization methods were used during allocation of subjects to different experimental groups in the study. Furthermore, no blinding was performed in the study.
Inclusion criteria
Clinically diagnosed and histologically confirmed cases of LSD muscle samples (based on routine histology and Oil-red-O staining) included in the study were from patients of age group 14-25 years. The patients selected for the study had 2-11 years duration of illness. Only cases with Medical research council scale for muscle strength between 3 and 5 were considered (Paternostro-Sluga et al.
2008).
Exclusion criteria
Mitochondrial myopathy (MM) cases, which represent primary mitochondrial impairment, were excluded. Accordingly, none of the cases in our study had any MM-related symptoms. Samples with age > 40 years were excluded.
Biopsy from paraspinal muscle of patients (n = 10) undergoing spinal surgery was collected from the neurosurgery department of NIMHANS as controls and stored, as previously described for the patient samples. Comparison of the histological and mitochondrial profile of paraspinal, biceps and quadriceps muscle types was carried out earlier (Sunitha et al. 2016 ) using postmortem biopsies from three healthy subjects with no history of neuromuscular disease, who died as a result of road traffic accidents. In all cases, samples were procured after obtaining written informed consent.
Histopathology and electron microscopy
Cryosections [8-lΜ-thick transverse sections of frozen muscle cut in a cryostat (Leica, Wetzlar, Hesse, Germany) at À20°C] were subjected to Haematoxylin & Eosin (H&E) staining, Oil-red-O staining, modified Gomori's trichrome staining and enzyme histochemistry [Nicotinamide adenine dinucleotide tetrazolium reductase (NADH-TR), succinic dehydrogenase (SDH) and combined cytochrome oxidase-SDH-cytochrome oxidase] (Dubowitz and Sewry 2007) . The tissues fixed in 3% glutaraldehyde were processed for electron microscopy (EM) (Sunitha et al. 2016) .
Preparation of mitochondria
Muscle mitochondria were prepared as described (Bhattacharya et al. 1991) with minor modification (Ramadasan-Nair et al. 2014). The modification was regarding the % of Nagarse with 10% used in our study instead of 20% as indicated in the original protocol. Briefly, muscle tissue (100 mg) was minced and incubated with 10% Nagarse in ionic medium (100 mM Sucrose, 10 mM EDTA, 100 mM Tris-HCl, 46 mM KCl, pH 7.4) for 5 min, washed with ionic medium containing 0.5% BSA, homogenized and centrifuged (500 g, 10 min; 4°C). The supernatant was centrifuged (12 000 g, 10 min; 4°C), and the partially purified mitochondrial pellet was washed twice with ionic medium containing 0.5% BSA and the final pellet was stored at À80°C in suspension medium (230 mM mannitol, 70 mM sucrose, 0.02 mM EDTA, 20 mM Tris-HCl, 5 mM K 2 HPO 4 , pH 7.4). Mitochondrial enrichment was confirmed by EM observation and rotenone sensitivity (Ramadasan-Nair et al.
2014).
Mitochondrial enzyme assays
Mitochondrial complex I (EC 1.6.5.3) (CI), complex II (CII) (EC 1.3.5.1), complex III (CIII) (EC 1.10.2.2) and complex IV (EC 1.9.3.1) were assayed using freshly prepared mitochondria isolated from different muscle samples. CI activity was assayed as described (Trounce et al. 1996) and rotenone-sensitive specific activity was calculated. Similarly, CII, CIII and CIV were assayed as described previously (Trounce et al. 1996) .
(a) CI assay: CI assay was initiated by adding 5 lg of muscle mitochondria to 50 mM Tris-HCl pH 7.4, 500 lM EDTA, 1% BSA, 200 lM NADH and 200 lM decylubiquinone with or without 2 lM rotenone, in the presence of 2 mM NaCN and 0.002% 2,6-dichloroindophenol (secondary electron acceptor). The decrease in the absorbance at 600 nm was recorded at 37°C for 10 min as a measure of the rate of enzyme reaction. Results were plotted as rotenone-sensitive specific activity.
(b) CII assay: The CII assay was initiated by addition of muscle mitochondria (10 lg protein) to the reaction mixture containing 10 mM Tris-HCl, pH 7.8, 2 lM EDTA, 10 mM succinate, 0.1% BSA, 3 lM rotenone, 1 lM antimycin, 0.3 mM of KCN, 80 lM 2,6-dichloroindophenol and 50 lM decyl-ubiquinone (added just before the reaction). The decrease in the absorbance at 600 nm was recorded 37°C for 10 min as a measure of the rate of enzyme reaction and specific activity was calculated.
(c) CIII assay: The specific activity of CIII was measured by following the reduction in cytochrome c (extinction coefficient for cytochrome c ¼ = 18.7/mM/cm) at 550 nm in a reaction mixture consisting of 50 mM potassium phosphate pH-7.2, 5% BSA, 30 mM n-dodecyl-b-D-Maltoside, 2.5 mM cytochrome c, 1 mM KCN, 3 lM rotenone, 10 mM reduced decyl-ubiquinone and 30 lg muscle mitochondria.
(d) CIV assay: CIV activity was measured by following the oxidation of reduced cytochrome c at 550 nm for 2 min. The reaction mixture containing 40 mM potassium phosphate (pH-7.0), 0.1% fatty acid free BSA, 2.5 mM lauryl maltoside and 20 lg of muscle mitochondria was initiated by addition of reduced cytochrome c (40 lM) and this reaction was inhibited up to 90% by KCN.
The activity of citrate synthase enzyme (E.C. 2.3.3.1) was measured by adding 10 mM oxaloacetate (20 ll) to the reaction mixture containing 100 mM Tris-HCl (pH 8.1), 0.2 mM 5,5 0 -dithio-bis-(2-nitrobenzoic acid) (DTNB), 0.1% Triton X-100, 0.1 mM acetyl-CoA and 2 lg protein (from fresh mitochondria) and the reaction was monitored at 412 nm (Srere, 1969) . Citrate synthase activity was expressed as nmol DTNB/min/mg protein (MEC = 13.6/mM/cm). Aspartate aminotransferase (AST) (E.C. 2.6.1.1) was assayed using a commercial kit (Grenier Bio-One GMBH). Total protein extract from freshly prepared mitochondria (10 lg) from LSD muscle biopsies and control muscle was subjected to the assay in triplicate, based on the manufacturer's instructions.
Malate dehydrogenase (EC 1.1.1.37) (MDH) activity was assayed as previously described (Kitto and Lewis 1967) and the specific activity was expressed as nmol NADH/min/mg protein (MEC 6.22 9 10 6 per cm/mol).
Estimation of ADP/ATP ratio ADP/ATP ratio was determined in freshly prepared total muscle extract from LSD cases and control using a commercial kit (Abcam) according to the manufacturer's instructions.
Quantitative mitochondrial proteomics
Sample preparation and TMT labelling Total mitochondria isolated from control muscle samples (n = 5, individually processed for mitochondrial isolation and named C1-C5) and LSD patients (n = 5, individually processed for mitochondrial isolation and named LSD1-LSD5) were suspended in 0.5% sodium dodecyl sulfate. The suspension was lysed using sonication followed by centrifugation at 21 952 g for 30 min. The supernatant containing solubilized proteins was transferred to another tube and subjected to protein estimation by bicinchoninic acid assay (Yalamati et al. 2015) (Pierce, Rockford, IL, USA). Equal amount of protein (250 lg) from each sample was reduced and alkylated using 10 mM of dithiothreitol and iodoacetamide respectively. Alkylated proteins were then digested using sequencing grade modified trypsin (Promega) at 37°C for 12 h and the tryptic digests evaporated to dryness. Digested peptides were then labelled with TMT reagent as per the manufacturer's protocol. Control samples (C1-C5) were labelled with 126 (C1), 127N (C2), 127C (C3), 128N (C4) and 128C (C5) TMT channels. Remaining TMT channels were used to label peptides from LSD samples LSD1-LSD5, i.e. 129N (LSD1), 129C (LSD2), 130N (LSD3), 130C (LSD4) and 131 (LSD5). The labelling efficiency for each sample was checked by analysing 2 lg equivalent peptides from each sample on the mass spectrometer followed by pooling of equal amount of labelling peptides from control and LSD samples. The pooled sample was dried and fractionated into six fractions using strong cation exchange chromatography-StageTip (Empore Solid Phase Extraction Disk) (Rappsilber et al. 2007) . Each fraction was then desalted using C18 stage-tips and subjected to liquid chromatography tandem mass spectrometric analysis.
Mass spectrometry
Each fraction was analysed in duplicate runs on Thermo Orbitrap Fusion tribrid mass spectrometer interfaced with Easy-nLC 1000 system (Thermo Scientific, Bremen, Germany) (Pawar et al. 2011) . The peptides were loaded on 2 cm Acclaim PepMapC18 precolumn (Thermo Fisher Scientific) and further resolved on 25-cmlong C18 column (3 lm, 100 A) using a linear gradient of 5% to 30% of solvent B (0.1% formic acid in 95% Acetonitrile) over 110 min. The data were acquired in data-dependent top speed mode with 3 s duty cycle. MS scans were acquired in 400-1600 m/z mass range using Orbitrap resolution of 120 000. Automatic gain control target and ion injection time was set to 200 000 and 55 ms respectively. The dynamic exclusion of precursor ions was enabled for 30 s with 7 ppm mass tolerance. The most intense precursor ions were fragmented using high-energy collision dissociation with 37% collision energy and the product ions were acquired in 110-2000 m/ z range with 30 000 Orbitrap resolution. Synchronous precursor selection was enabled for MS3 scans and top seven precursor ions were selected for fragmentation. High-energy collision dissociation collision energy of 55% was applied and product ions were acquired in 110-600 m/z range using Orbitrap. A resolution of 60 000 was used for MS3 scans with automatic gain control target of 50 000 and 150 ms ion injection time. Internal calibration was enabled using lock mass option (m/z 445.1200025) from ambient air.
Data analysis
The mass spectrometry-derived raw data were searched against Human RefSeq protein database (version 75) using Mascot (version 2.4.1) and Sequest search engines on Proteome Discoverer 2.1 suite (Sunitha et al. 2016) . Trypsin was selected as the proteolytic enzyme and one missed cleavage was allowed during the search. Precursor and fragment ion mass tolerance were set to 10 ppm and 0.05 Da respectively. Carbamidomethylation of cysteine, TMT labelling at peptide N-terminus and lysine were selected as static modification and oxidation of methionine was set as dynamic modification. Percolator was used to compute false discovery rate by employing a decoy database search and the data were filtered at 1% peptide spectrum matches level false discovery rate. Reporter ion quantifier node was used to estimate relative quantitation of TMT channels from MS3 scans and normalization option was enabled. Gene ontology analysis was carried out using Database for Annotation, Visualization and Integrated Discovery (DAVID) web resource (da Huang et al. 2009 ). Protein-protein interactions were predicted using STRING resource with default parameters (Szklarczyk et al. 2015) . For all differentially expressed proteins, cut-off values of ≥ 1.5 fold (over-expression) and ≤ 0.7 fold (down-regulation) were considered.
Statistical analyses
Quantitative data represented by bar graphs were accumulated from at least three independent experiments and expressed as mean AE SD. Assessment of normality and test for outliers on the data were not included. All analyses were performed using GraphPad Prism software; GraphPad Software Inc., La Jolla, CA, USA. For data related to validation experiments, analysis of variance (ANOVA) analysis was performed and p value < 0.05 was considered as significant. For the MS experiment, data regarding the list of proteins and corresponding fold-changes across the replicates compared with the corresponding controls were uploaded on Perseus software (http://www.perseus-framework.org) for calculation of p value and generation of heat maps (Tyanova et al. 2016) .
Results
Histological characteristics of muscle biopsy from LSD patients For morphological analysis [(routine histology, enzyme histochemistry and ultrastructural analysis (EM)], biochemical and proteomic experiments in muscle samples, we utilized paraspinal muscle from subjects with non-neuromuscular conditions (n = 10) and biceps/quadriceps with non-diagnostic pathology (n = 3) as control (Table 1) . Previously, we demonstrated that the biceps, quadriceps and paraspinal muscles showed significantly comparable mitochondrial function as indicated by similar enzyme activities of citrate synthase, respiratory complexes, subunit composition of respiratory complexes and ADP/ATP ratio (Sunitha et al. 2016) . Muscle biopsies from clinically, biochemically and histopathologically characterized cases of LSD (n = 7) were selected (Table 1) . Routine HE staining of muscle sections from LSD biopsies indicated polygonal to round fibres with several fibres displaying multiple fine vacuoles leading to a sieve-like appearance, compared to control (Fig. 1a) . Oilred-O staining of the sections revealed prominent multiple red deposits suggesting significant intracellular accumulation of lipids (Fig. 1b) .
Mitochondrial changes in muscle pathologies
Mitochondrial dysfunction was evident in LSD muscle biopsies based on the presence of typical ragged-red fibres (RRFs) (in addition to vacuolation) on modified Gomori's trichrome stained muscle sections (Fig. 1c) as described earlier for muscle pathologies with mitochondrial dysfunction in general (Rifai et al. 1995; Vogel 2001; Challa et al. 2004; Alston et al. 2017) and in cases of LSD (Uppin et al. 2008) . RRFs were observed in six cases. The average type I fibres with RRF and hypermetabolic fibres in LSD cases were 50%. Mitochondrial damage was also inferred by the presence of intensely stained hypermetabolic fibres, based on SDH staining (Fig. 1d) and presence of an occasional combined cytochrome oxidase-deficient fibre in one case, compared to control tissue (Fig. 1e) .
Mitochondrial damage in muscle pathology could involve either sub-sarcolemmal mitochondrial aggregation and/or altered morphology. Ultrastructural analysis of LSD muscle revealed preserved sarcolemmal membrane (data not shown), appearance of intracellular lipid droplets (Fig. 2c) and disarray of myofibrils and focal loss of connectivity of myofilaments in many fibres (Fig. 2d-e) , compared to control. Some mitochondria revealed elongated structure and accumulation of electron dense material and lipid droplets ( Fig. 2e-f ).
Mitochondrial dysfunction in LSD was also evident by significant increase in ADP/ATP ratio compared to control (Fig. 3a) . Enzyme assays carried out on muscle mitochondria from LSD cases versus control revealed significant loss of activity of respiratory complexes I-IV (Fig. 3b-e) . Similarly, the Krebs cycle enzyme MDH showed~80% inhibition of activity (Fig. 3f) , while AST also showed~80% inhibition of activity (Fig. 3g) in LSD muscle tissue, compared to control.
Combining the histochemical, biochemical and ultrastructural data, it could be surmised that mitochondrial dysfunction is evident in the LSD muscle. To characterize the mitochondrial dynamics at the molecular level, we next compared the mitochondrial proteomic changes in LSD muscle compared with control samples. This approach would also reveal whether the lowered activity of mitochondrial enzymes observed in LSD samples was caused by altered protein expression.
Mitochondrial proteomic changes in muscle pathologies
We compared the mitochondrial proteomic profile in LSD muscle samples (n = 5) ( Table 2 ) with healthy controls (n = 5) by isobaric tag for relative and absolute quantitation labelling of the mitochondrial extracts from individual cases [TMT labelling for control (C) cases: C1 = 126, (ii) Paraspinal (n = 10) 6 : 4 1-25 N/A 2.
Lipid storage disorder (LSD)
Biceps/quadriceps (n = 7) 3 : 4 14-25 2-11 N/A, not applicable.
Fig. 1
Histological characterization and analysis of mitochondrial damage in muscle biopsies from human lipid storage disorder (LSD) subjects and control. Skeletal muscle biopsy from suspected LSD cases (n = 7 samples) and age-matched normal controls (n = 3 samples) with non-diagnostic pathology [biopsies exhibiting normal histology and unchanged expression of all muscle proteins: dystrophin, sarcoglycans-a, b, c and d and merosin were used as controls (data not shown)] were subjected to routine histology and enzyme histochemistry using standard methods. Representative images are shown for control and LSD cases. (Fig. 4a) . Analysis of MS data revealed that among the 266 mitochondrial proteins [as identified by Human Mitocarta (Calvo et al. 2016) ] from a total of 772 proteins, 98 proteins were differentially expressed, with 38 up-regulated (≥ 1.5-fold) and 60 down-regulated (≤ 0.7-fold) proteins across all LSD samples compared to control (Fig. 4b and Tables 3 and 4) . Gene Ontology analysis of the biological processes and pathways of all the identified proteins is summarized in Figures S1 and S2 . Accordingly, 68% of over-expressed proteins were linked with the metabolic pathways including oxidative phosphorylation and FA metabolism. Similarly, 63% of the proteins down-regulated were linked with metabolic pathways including amino acid metabolism. Analysis of the proteomic data for clustering of related genes in specific pathways by DAVID analysis showed that the differentially regulated proteins were predominantly part of FA metabolism (n = 16), respiratory complexes (RC) and their assembly (n = 17) and Tricarboxylic acid (TCA) cycle (n = 16) ( Fig. 5a and b) . Among the proteins contributing to the RC complexes and their assembly, nine proteins were upregulated and eight proteins were down-regulated (Fig. 5b) . Apart from this, a few proteins linked with antioxidant function (n = 6) and mitochondrial permeability transition pore (mPTP) (n = 3) were differentially expressed.
Most of the proteins involved in FA metabolism and TCA cycle were down-regulated compared to control (14 of 16 proteins of FA metabolism and 15 of 16 proteins of TCA cycle) (Fig. 5b) . Consistent with the lowered activity of the Krebs cycle enzyme MDH (Fig. 3f) , MS data showed that the protein was down-regulated with the peroxisomal isoform (MDH1) down-regulated to 0.4-fold versus control, while the mitochondrial isoform was down-regulated to 0.3-fold in LSD versus control (Table 4) . On the other hand, AST (Mitochondrial isoform GOT2) was down-regulated to 0.5-fold in LSD versus control in LSD muscle tissue, compared to control (Table 4 ) consistent with lowered activity as shown in Fig. 3(g) . Apart from these, other proteins (n = 40) with physiologically relevant mitochondrial functions including mitochondrial architecture and metabolism showed differential regulation.
Next, we assessed the expression of individual proteins across individual LSD patients. Heat-maps of the expression profile of specific proteins belonging to FA metabolism, RC and assembly and TCA cycle, showing opposite trend in LSD versus control across all the five individual samples are indicated in Fig. 6a-c . The overall expression trend of these proteins in the three pathways was comparable across LSD samples and controls. Interactome assessment based on string analysis of all differentially regulated proteins of different groups revealed high interaction among constituent proteins (Fig. 6a-c) , with the strongest interaction noted among the proteins of the TCA cycle. Interactome analysis of all 98 differentially expressed mitochondrial proteins showed significantly interlinked functional interaction ( Figure S3 ). These data indicate that while impaired LS morphologically manifests as lipid accumulation and mitochondrial dysfunction, it is biochemically linked to metabolic disruption of FA metabolism, electron transport chain and TCA cycle Fig. 3 Biochemical analysis of mitochondrial alterations in LSD. Evidences of mitochondrial damage were recorded in LSD samples versus age-matched controls by assessment of ADP/ATP, activities of respiratory complexes and other enzymes in skeletal muscle biopsy. LSD muscle extract displayed significant increase in ADP/ATP ratio compared to control (**p < 0.01 compared to control) (a). Lowered activities of respiratory complexes I (CI) (b), complex II (CII) (c), complex III (CIII) (d) and complex IV (CIV) (e) in muscle mitochondria from LSD patients (n = 7 samples), compared to control (n = 5 samples); **p < 0.01 and ***p < 0.001 compared to control. (f) Decreased activities of the TCA cycle enzyme malate dehydrogenase (MDH) and aspartate aminotransferase (AST/GOT2) in muscle mitochondria from LSD patients (n = 7 samples), compared to control (n = 5 samples). ***p < 0.001 and ****p < 0.0005 compared to control. ultimately leading to lowered ATP content. The synergistic effect following interaction among these pathways ( Figure S2 ) predominantly contributes to mitochondrial dysfunction.
We next assessed whether the profile of differentially expressed mitochondrial proteins was unique to LSD or common to other muscle pathologies. In our previous study, we compared the mitochondrial protein profile in dysferlinopathy (Dysfy) (representative of dystrophic pathology), DMRV and polymyositis (PM) (representative of inflammatory pathology) (Sunitha et al. 2016) . Our data indicated that among the unique down-regulated proteins in the three groups, PM had only 3, while dysfy and DMRV had 32 and 26 proteins, respectively (with 24 proteins common between them), indicating that DMRV and dysfy possess certain uniqueness in mitochondrial dynamics. However, 80 proteins were common among the three pathologies. Comparison of the LSD data with these three pathologies revealed that among the down-regulated mitochondrial proteins, 33 were common while 16 were unique to LSD. On the other hand, only two up-regulated proteins in LSD samples were common with the other three muscle pathologies, while 35 were unique to LSD (Fig. 7a) . Interactome analysis revealed significant interaction among differentially expressed proteins common among LSD and other muscle pathologies (n = 35), and among proteins unique to LSD (n = 51) (Fig. 7b) .
In addition, we checked the mass-spectrometer derived data for potential post-translational modifications. Even though we did not carry out enrichment of phosphopeptides, we could identify a phosphopeptide from myosin light chain 2 (MYL2), which indicated hyperphosphorylation at Ser 15 by 27.7-fold in LSD patients compared to controls. This phosphopeptide was not identified in the proteomic analysis of other pathologies [Centronuclear myopathy, Duchenne muscular dystrophy, Sacroglycanopathy, Dysfy, DMRV and PM) and the abundance of the phosphorylated peptide in LSD could be one of the reasons behind its identification in MS data ( Fig. 8 and data not shown). At the protein expression level, multiple peptides suggested significant depletion of the protein in each of the disease conditions mentioned above, including LSD (Data not shown).
Discussion
Varied stimuli and downstream effects entail mitochondrial dysfunction in non-mitochondrial pathologies Recently, we observed that inhibitors of mitochondrial respiratory complexes not only influenced the mitochondrial function but also the nuclear genome (Mythri et al. 2017 and Ranganayaki et al., unpublished) . Interestingly, the global transcriptomic changes induced by an inhibitor of CI (1-methyl-4-phenylpyridinium iodide) were significantly different from those induced by a CII inhibitor (3-nitropropionic acid) and a non-mitochondrial toxin (Manganese). These data further corroborate that while the upstream stimulus potentially determines the nature of mitochondrial events, the molecular changes that entail mitochondrial dysfunction and the downstream effects could vary in different pathologies. For instance, analysis of the mitochondrial proteome in muscle pathologies revealed that apart from common events, several pathways/proteins were altered in a disease-specific manner indicating that mitochondrial function is affected to a different extent. Protein oxidation events affecting mitochondrial proteins are also different among different human muscle pathologies (Sunitha et al. 2016) . On similar lines, abnormal cellular storage events influence mitochondrial function. While formation of LDs to avoid excessive FAs could affect the mitochondrial function (Greenberg et al. 2011; composition of mitochondrial membrane could potentially result in mitochondrial dysfunction (Platt et al. 2012) .
The juvenile visceral steatosis (JVS) mouse is an in vivo model of abnormal lipid metabolism exhibiting systemic carnitine deficiency. The cardiac and skeletal muscle in the JVS mouse exhibit RRFs, increased number of mitochondria and lipid droplets leading to distorted myofibril bundles, thereby indicating cardiac and skeletal muscle dysfunction (Miyagawa et al. 1995) . These morphological features are recapitulated in the human LSD muscle analysed in our study (Figs 1 and 2) . Although the JVS muscle is a relevant model to link abnormal lipid storage with mitochondrial dysfunction, we surmised that analysis of muscle from individual LSD patients exhibiting varied deficiencies of lipid Muscle mitochondria isolated from LSD patients and healthy controls individually, were subjected to tryptic digestion and TMT labelling followed by LC-MS/MS analysis and data analysis. The Refseq accession number, gene symbol, protein description and fold change in expression (compared to control) of the over-expressed proteins and p value are shown. metabolism would provide better representation and encompass most of the mitochondrial changes pertinent to humans. Another reason to rely on human samples was to compare mitochondrial changes in LSD with other non-mitochondrial human pathologies such as dystrophies and related myopathies (Fig. 7) . We had previously carried out characterization of mitochondrial dysfunction and oxidative damage using experimental models of muscle degeneration (RamadasanNair et al. 2014) . In that study, we characterized an acute transient cardiotoxin mouse model of muscle degeneration and highlighted the role of mitochondrial dysfunction and oxidative damage and compared the same with human pathologies using muscle biopsies. Using such models and human samples (Sunitha et al. 2016) , our objective has been to compare the mitochondrial proteome from non-mitochondrial pathologies with primary mitochondria disorders.
Mitochondrial proteomics reflect the neurometabolic nature of LSDs
We observed that apart from morphological alterations in the muscle mitochondria from LSD subjects (Fig. 2a-f) , differential expression of mitochondrial proteins belonging to FA metabolism, TCA cycle and respiratory complexes and mitochondrial membrane potential (Fig. 5b) could synergistically contribute to muscle pathology. For instance, upregulation of proteins contributing to lipolysis could alter lipid homeostasis. Accordingly, LACTB, a Serine betalactamase that regulates mitochondrial lipid metabolism (Keckesova et al. 2017 ) was found to be up-regulated in LSD by > 2.3-fold compared to control (Table 3) . Interestingly, many of the down-regulated proteins associated with lipid metabolism in LSD muscle are linked with human diseases. Acetyl-CoA acetyltransferase 1 (down-regulated by 60% in LSD, Table 4 ) is a unique thiolase which contributes to FA and ketone body metabolism. Deficiency of acetylCoA acetyltransferase 1 leads to ketothiolase deficiency, an autosomal recessive condition causing increased cholesterol and its metabolites, altered isoleucine metabolism, organic acidemia, ketosis and hypoglycaemia (Adams and Venditti 2007) . Another down-regulated protein is enoyl coenzyme A hydratase, short-chain, 1, deficiency (down-regulated by 60% in LSD, Table 4 ) involved in beta oxidation of FAs. Lowered activity of this enzyme is associated with mitochondrial short-chain enoyl-CoA hydratase deficiency, an autosomal metabolic condition with significant neurological symptoms (Peters et al. 2014; Yamada et al. 2015) . Many TCA cycle enzymes down-regulated in LSD samples are also linked with human disease. For instance, Pyruvate dehydrogenase protein X component (PDHX), an important component in the TCA cycle, which anchors dihydrolipoamide dehydrogenase (E3) to the dihydrolipoamide transacetylase (E2) core of the PDH complex, is down-regulated by 60% in LSD compared to control (Table 4) . Deficiency of PDHX is known to cause congenital lactic acidosis, a metabolic disorder associated with hypotonia and psychomotor retardation (Aral et al. 1997) . MDH2, an integral component of the TCA cycle, was downregulated by 70% in LSD compared to control (Table 4) . Apart from these, altered amino acid metabolism closely linked with metabolic processes such as the TCA cycle is probably affected in LSD. Aldehyde Dehydrogenase 4 Family Member A1, down-regulated up to 80% in LSD (Table 4) , is involved in the irreversible conversion of delta-1-pyrroline-5-carboxylate (P5C), derived either from proline or ornithine, to glutamate. This is an important step in the pathway interconnecting the urea and TCA cycles. Mutations in the gene Aldehyde Dehydrogenase 4 Family Member A1 lead to elevated serum levels of proline and delta-1-pyrroline-5-carboxylate (P5C), resulting in Hyperprolinemia 2, a metabolic condition with neurological symptoms including seizures, intellectual deficit and mild developmental delay (Geraghty et al. 1998; Srivastava et al. 2012) .
We observed that altered mitochondrial membrane potential could also contribute to mitochondrial dysfunction in LSD. Accordingly, proteins voltage-dependent anion channel 1, voltage-dependent anion channel 2 and solute carrier family 25, member 3 (SLC25A3), which regulate the membrane permeability transition (mPTP) were up-regulated in LSD, by 1.7-, 1.6-and 1.6-fold respectively (Table 3) . This could be specific to LSD as these proteins were not upregulated in Dysfy, DMRV and PM (Fig. 7) (Sunitha et al. (Table 3  and 4) .
In an interesting study (Wauthier et al. 2006) , it was demonstrated that ageing is associated with increased expression of the cytochrome P450 isoform E1 (CYP2E1) but decreased activity in rats, posing a paradox. Similarly, our data revealed that among the 38 up-regulated proteins, 9 (~23% of up-regulated proteins) are part of RC complexes (Fig. 5b) contributing to oxidative phosphorylation, while their activities were diminished (Fig. 3b-e) . We believe that altered mitochondrial function is not only associated with down-regulation but also up-regulation of mitochondrial proteins, as evident from the over-expression of proteins associated with the mitochondrial membrane potential described earlier. We speculate that elevated expression of subunits of respiratory complexes could probably alter activity by altering/disrupting complex assembly, disrupting the active centres, promoting aggregation, causing inaccessibility to the substrate, probably via post-translational modifications, oxidative damage or other biochemical phenomena (Wauthier et al. 2006) . Furthermore, eight proteins belonging to RC complexes were down-regulated, which could also contribute to lowered activity (Fig. 5b) .
Altered myosin phosphorylation in LSDs
Our proteomics data indicated significantly higher phosphorylation of myosin light-chain MYL2 at ser 15 (Fig. 8) .
Phosphorylation of MYL2 alters myosin motor structure and potentially enhances the Ca 2+ sensitivity of the contractile machinery in the skeletal muscle thereby modulating its basic mechanical properties and enhancing the dynamic function of skeletal muscle. This phenomenon is directly related to the performance of the skeletal muscle in the unfatigued or fatigued state with implications for disease (Stull et al. 2011) . In this context, the quantitative analysis of MYL2 phosphorylation selectively in LSD and not in other diseases including Dysfy, DMRV and PM (Fig. 8 and data not shown) poses an interesting paradigm about muscle use and fatigue, rate of contraction and mechanical properties of the contraction apparatus in disease.
In conclusion, our data indicate that several inter-related mitochondrial pathways including metabolic, structural and redox mechanisms could contribute to mitochondrial damage and altered lipid storage in the skeletal muscle of LSD patients (Fig. 9) . However, the mechanisms that culminate from this stage until the manifestation of muscle pathology are not completely ascertained in human tissues. Although some of the pathways are common with other muscle pathologies, there are several proteins and pathways that are uniquely altered in LSD, with implications for pathobiology and therapeutics.
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